Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference

Novan, Inc. today announced that preclinical data demonstrating the anti-viral effects of the Company’s nitric oxide-releasing drug candidates will be presented at the 31st International Papillomavirus Conference in Cape Town, South Africa. Thomas Broker, Ph.D., and Louise Chow, Ph.D., both of the University of Alabama at Birmingham, or UAB, are scheduled to present “Antiviral Efficacy of Nitric Oxide-Releasing Drug Candidates in Suppressing Productive Infection by HPV-18 in the Organotypic Epithelial Raft Culture Model System” on Thursday, Mar. 2. Drs.

Virginia Tech researchers receive NIH grant to improve malaria drug

As long as parasites continue to mount resistance to malaria drugs, scientists will be faced with the task of developing new, improved pharmaceuticals. A research team from the Virginia Tech Center for Drug Discovery has received a $431,126 two-year grant from the National Institutes of Health to make improved versions of a promising compound called MMV008138, or 8138 for short.

Jefferson researchers reveal new insight into two states of viral protein

To generate swarms of new viral particles, a virus hijacks a cell into producing masses of self-assembling cages that are then loaded with the genetic blueprint for the next infection. But the picture of how that DNA is loaded into those viral cages, or capsids, was blurry, especially for two of the most common types of DNA virus on earth, bacterial viruses and human herpesvirus.